deltatrials
Terminated PHASE1 INTERVENTIONAL 4-arm NCT03906526

A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

A Phase 1b Multicenter Pre-Surgical Study to Evaluate Immune Biomarker Modulation in Response to Motolimod (VTX-2337) in Combination With Nivolumab in Subjects With Resectable Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Sponsor: Celgene

Conditions Carcinoma, Squamous Cell
Interventions Nivolumab VTX-2337
Updated 16 times since 2019 Last updated: Feb 23, 2023 Started: Jul 3, 2019 Primary completion: Jan 24, 2022 Completion: Jan 24, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Business objectives have changed

Other terminated trials from Celgene

See all terminations from Celgene

Other Carcinoma, Squamous Cell trials with similar outcome

Browse all Carcinoma, Squamous Cell trials

A PHASE1 clinical study on Carcinoma, Squamous Cell, this trial is terminated or withdrawn. The trial is conducted by Celgene and has accumulated 16 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~May 2019 – ~Oct 2019 · 5 months · monthly snapshot~Oct 2019 – ~Feb 2020 · 4 months · monthly snapshot~Feb 2020 – ~May 2020 · 3 months · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Nov 2021 · 8 months · monthly snapshot~Nov 2021 – ~Mar 2022 · 4 months · monthly snapshot~Mar 2022 – ~Mar 2023 · 12 months · monthly snapshot~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  4. Mar 2023 — Jul 2024 [monthly]

    Terminated PHASE1

    Status: Completed → Terminated

  5. Mar 2022 — Mar 2023 [monthly]

    Completed PHASE1

    Status: Recruiting → Completed

▶ Show 11 earlier versions

  1. Nov 2021 — Mar 2022 [monthly]

    Recruiting PHASE1

  2. Mar 2021 — Nov 2021 [monthly]

    Recruiting PHASE1

  3. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1

  4. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  5. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE1

  6. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE1

  7. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE1

  8. May 2020 — Jul 2020 [monthly]

    Recruiting PHASE1

  9. Feb 2020 — May 2020 [monthly]

    Recruiting PHASE1

  10. Oct 2019 — Feb 2020 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  11. May 2019 — Oct 2019 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celgene
Data source: Celgene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations